Search
Restoring Effective Anti-Tumor Response in Hodgkin Lymphoma with Nivolumab
Hodgkin Lymphoma typically affects young men and women in their 30s. Although it is highly curable with the current combination of chemo and radiation therapy, approximately 20% of patients will not be cured with first line regimens.
Read moreEHA-SLCH Hematology Tutorial on Myeloid Malignancies and MDS
Dates: February 8-9, 2019
Location: Colombo, Sri Lanka
Chairs: G Ossenkoppele, V Gunawardena, HW Goonasekera
After a successful first edition in 2017, EHA is organizing the second two-day tutorial in close collaboration with the Sri Lanka College of Haematologists (SLCH) on "Myeloid malignancies and MDS".…
EHA in the BioMed Alliance: joining forces for biomedical research
At a recent meeting at the European Parliament, Prof.
Read moreEHA-EBMT 2nd European CAR T Cell Meeting
Dates: January 30 – February 1, 2020
Location: Sitges (Barcelona), Spain
Chairs: H Einsele, C Chabannon
The 2nd edition of this meeting is jointly organized by the European Hematology Association (EHA) and the European Society for Blood and Marrow Transplantation (EBMT).…
Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.
The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.
Would you sell Peripheral Blood derived Stem Cells?
There are many things that are different in the United States of America (USA) and Europe. Some of these differences are in favour of society in the USA and some in Europe.
Read morePublications
Experience With IVDR Implementation in Three Diagnostic Laboratories: Messages to EU Health Institutions, Diagnostic Healthcare Payers, and Authorities
Lubbers BR, Dombrink I, Kalina T, Hofmans M, Bruun MS, Stanworth SJ, Béné MC, Döhner K, Brüggemann M, Macintyre E, van Dongen JJM.…
The new EU clinical trials map is online
A new clinical trial map was launched by EMA as part of the Clinical Trials Information System (CTIS) on March 3.
Read moreMajor bleeding in patients on treatment with NOACs or VKAs in real-life: clinical presentation, management and outcome
Major bleeding in patients on treatment with NOACs or VKAs in real-life: clinical presentation, management and outcome
Limited data are available on major bleeding (MB) occurring during treatment with vitamin K (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs) outside clinical…